Article in The Lancet Infectious Diseases on RIVM research into Maternal pertussis vaccination Scientific journal The Lancet Infectious Diseases has published an article on RIVM research conducted into pertussis vaccination for pregnant women.
Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Vaccination schedule for babies reviewed after introduction whooping cough vaccination for pregnant women Whooping cough is a dangerous disease for new born, unvaccinated babies. Starting at the end of 2019, the whooping cough vaccination will be offered nationwide to pregnant women.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Citizen Science Magazine; everyone's a scientist “RIVM is committed to being innovative, and becoming a key player in citizen science is fully in line with that goal,” says Danielle Timmermans, Chief Science Officer for Risk Communication at RIVM
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.